Sign up
Tech Capital

Amphion Innovations pinning hopes on Polarean Inc after Motif Bio success

Richard Morgan, chief executive of Amphion PLC (LON:AMP), discusses the 'very welcome' Phase III Iclaprim news from Motif Bio.

Motif's recently revealed its lead drug, a next generation antibiotic, successfully negotiated a crucial final-stage clinical study, boosting Amphion’s shares.

Amphion owns 14.1% of Motif Bio.

Morgan says he continues to believe that Motif Bio is not fully valued compared to other comparable antibiotic companies at the same stage of development.

 

View full AMP profile

Amphion Innovations Plc Timeline

View All

© tech Capital 2017

Tech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed tech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Tech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Technology market.